Pick the same day each week for consistency
For those targeting specific problem areas, understanding peptides for visceral fat loss provides additional context
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Age, overall health, injury severity and chronicity, concurrent therapies , nutrition, sleep, and activity levels all influence outcomes
This approach follows general peptide cycling logic and is a reasonable precaution given limited long-term human data